Immunome, Inc. (IMNM)

Market Cap	686.53M
Revenue (ttm)	10.94M
Net Income (ttm)	-205.11M
Shares Out	87.01M
EPS (ttm)	-3.13
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	450,958
Open	8.35
Previous Close	8.56
Day's Range	7.83 - 8.45
52-Week Range	5.15 - 16.81
Beta	2.01
Analysts	Strong Buy
Price Target	26.40 (+234.6%)
Earnings Date	May 12, 2025

About IMNM

Immunome, Inc., a clinical-stage biotechnology company, develops targeted cancer therapies. The company’s clinical asset comprises Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. Its preclinical assets include IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, including IM-1617, IM-1340, and IM-13...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 2, 2020
• Employees: 118
• Stock Exchange: NASDAQ
• Ticker Symbol: IMNM
• Website: https://immunome.com

Financial Performance

In 2024, Immunome's revenue was $9.04 million, a decrease of -35.50% compared to the previous year's $14.02 million. Losses were -$292.96 million, 174.3% more than in 2023.

Analyst Forecast

According to 5 analysts, the average rating for IMNM stock is "Strong Buy." The 12-month stock price forecast is $26.4, which is an increase of 234.60% from the latest price.

Price Target

$26.4

(234.60% upside)

Analyst Consensus: Strong Buy